{
    "clinical_study": {
        "@rank": "30060", 
        "arm_group": {
            "arm_group_label": "Pioglitazone", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is being done to determine whether or not addition of the oral medication,\n      pioglitazone to standard chemotherapy, results in improvement of blood tests that measure\n      the body's ability to utilize sugar (glucose and insulin metabolism). In addition the\n      investigators want to determine whether or not treatment with pioglitazone results in (1)\n      improvement in the size of the tumor, (2) weight gain, (3) improved ability to function\n      during the day and (4) quality of life."
        }, 
        "brief_title": "A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas", 
        "condition": "Cancer of the Pancreas", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Histologically proven adenocarcinoma of the pancreas\n\n          -  Radiologically measurable disease\n\n          -  ECOG functional status  0-2\n\n        Exclusion Criteria:\n\n          -  Prior radiation therapy for pancreatic cancer If chemotherapy is planned, new\n             chemotherapy regimen should have started more than 14 days prior to enrollment\n\n          -  Surgery or radiation planned within 8 weeks of starting therapy\n\n          -  Prior exposure to Thiazolidinedione (TZD) therapy in the past 12 months\n\n          -  Hypersensitivity of TZD\n\n          -  New York heart association class III/IV heart failure.\n\n          -  Known HIV positive\n\n          -  Pregnant or lactating women\n\n          -  History of, or active bladder cancer\n\n          -  Inadequate hepatic function documented within 14 days of enrollment\n\n          -  Total bilirubin level > 1.5 x ULN\n\n          -  AST  and  ALT  > 2.5  x ULN,  unless  there  are  liver  metastases  in which case\n             AST and ALT or > 5 x ULN"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838317", 
            "org_study_id": "STU 072012-036"
        }, 
        "intervention": {
            "arm_group_label": "Pioglitazone", 
            "intervention_name": "Pioglitazone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pancrelipase", 
                "Pioglitazone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "UT Southwestern Medical Center"
            }, 
            "investigator": {
                "last_name": "Muhammad S Beg, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas", 
        "other_outcome": {
            "description": "Changes  in  ECOG  performance   status    in  patients   with   pancreas cancer receiving pioglitazone.", 
            "measure": "ECOG Performance Status", 
            "safety_issue": "No", 
            "time_frame": "Every 2 weeks for 10 weeks"
        }, 
        "overall_contact": {
            "email": "Muhammad.Beg@UTSouthwestern.edu", 
            "last_name": "Muhammad S Beg, MD", 
            "phone": "214-648-4673"
        }, 
        "overall_contact_backup": {
            "email": "tyson.Dudley@utsouthwestern.edu", 
            "last_name": "Tyson D Dudley, MBA, MPH", 
            "phone": "214-648-7031"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in serum adiponectin level. We will obtain serum levels of adiponectin at  baseline and after 8 weeks of treatment with pioglitazone.\nChanges in standard glucose tolerance test. We will perform the area  under the  oral  glucose tolerance test at baseline and after 8 weeks of treatment with pioglitazone.\nFasting levels of serum glucose and insulin. We will obtain serum  levels  of  fasting  glucose  and  insulin  every  four  weeks  in all patients receiving pioglitazone", 
            "measure": "Improvement in insulin resistance markers", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline 4 weeks and 8 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838317"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To describe changes in weight in patients with pancreas cancer receiving pioglitazone.", 
            "measure": "Change in weight", 
            "safety_issue": "No", 
            "time_frame": "Every 2 weeks for 10 weeks"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}